Exchange Traded Concepts LLC Buys 2,139 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Exchange Traded Concepts LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 53.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,159 shares of the biopharmaceutical company’s stock after purchasing an additional 2,139 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Regeneron Pharmaceuticals were worth $4,387,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the topic of several research analyst reports. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $675.79 on Friday. The company’s 50-day moving average price is $728.81 and its two-hundred day moving average price is $940.38. The firm has a market cap of $74.26 billion, a P/E ratio of 16.72, a P/E/G ratio of 1.59 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.